Beyond standard organoids: how Physioscaffolds de-risk preclinical pipelines in the era of FDA NAM guidelines
The global pharmaceutical industry operates under a costly paradox: nearly 95% of drug candidates validated in animal models ultimately fail in human clinical trials. This translation gap drains billions of dollars annually in wasted R&D expenditure and delays life-saving therapeutics from reaching patients. In response, global regulatory authorities are enacting an unprecedented paradigm shift: However,